Results 151 to 160 of about 37,214 (250)

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1731-1740, August 2026.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig   +5 more
wiley   +1 more source

Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2819-2827, August 2026.
This original research used medication administration data to explore adherence to treatment guidelines for the most common osteoporosis medications in long‐term residential aged care (RAC) in Australia. The paper highlights gaps in adherence to treatment guidelines that must be addressed to improve outcomes of older adults living in RAC.
Marea O'Donnell   +7 more
wiley   +1 more source

The physiology of survival: Space

open access: yes
Experimental Physiology, EarlyView.
Damian M. Bailey, Angelique van Ombergen
wiley   +1 more source

Calvarial Metastasis of Breast Carcinoma Manifesting as a New Daily Persistent Headache: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT New‐onset daily persistent headache (NDPH) is a primary headache syndrome characterized by a sudden onset of daily headaches persisting for more than three months in patients with no prior headache history. We report the case of a 49‐year‐old Indian lady who presented to the neurology outpatient clinic with new daily persistent headache.
Neha Lall   +3 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 334-344, August 2026.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

A Prospective Case Series on the Effect of Cross‐Linked Hyaluronic Acid Combined With a Collagen Sponge in the Treatment of Alveolar Osteitis

open access: yesClinical and Experimental Dental Research, Volume 12, Issue 4, August 2026.
ABSTRACT Objectives This case series reports on alveolar osteitis (AO) treatment outcomes after standard AO therapy combined with cross‐linked hyaluronic acid (xHyA) and a collagen sponge. Material and Methods Nine patients fulfilling the AO criteria after permanent tooth extraction were included.
Danijel Domic   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy